Catalent Pharma Solutions Expands Bloomington, Indiana, Operations
04/28/2022
The 1,000,000-square-foot biologics development and manufacturing facility specializes in sterile formulation and extensive biomanufacturing and drug product fill/finish capacity across liquid and lyophilized vials, prefilled syringes and cartridges.
"Our continued growth in Bloomington demonstrates how important this site has become to the production of medicines for patients worldwide,” said John Chiminski, Chair and CEO at Catalent. “We are immensely grateful for our close collaboration with the state of Indiana, the city of Bloomington, and state and local economic development organizations. The talented, diverse Hoosier workforce and the ambitious business environment provide a strong foundation for our long-term presence in Bloomington."
The Indiana Economic Development Corporation (IEDC) has committed an investment in Catalent of up to $40 million in the form of incentive-based tax credits and up to $2.5 million in conditional training grants based on the company’s job creation plans. The IEDC also committed an additional investment of up to $1.5 million redevelopment tax credits based on the company's investment plans. These tax credits are performance-based, meaning the company is eligible to claim incentives once Hoosiers are hired and trained and investments are made. The city of Bloomington offered additional incentives.
The Bloomington Economic Development Corporation (BEDC) has continued to provide strategic, advisory, and logistical support throughout this project.
"Indiana’s vibrant and unique life sciences industry continues to make a tremendous impact on the Hoosier state through its economic strength, contributing more than $79 billion in 2021," said Governor Eric J. Holcomb. "Indiana is making strategic investments in those businesses, like Catalent, to advance smart technologies and processes, and that investment has allowed Indiana to become the second largest exporter of life sciences products in the U.S. and is recognized as a world leader in the industry."
Catalent, Inc. is a multinational corporation headquartered in Somerset, New Jersey. The company is a global provider of delivery technologies, development, drug manufacturing, biologics, gene therapies and consumer health products. Catalent employs more than 14,000 people, including approximately 2,400 scientists and technicians.
Project Announcements
Hoover Treated Wood Products Plans Fairfield, Texas, Wood Treating Facility
03/30/2023
EnerVenue Establishes Shelby County, Kentucky, Manufacturing Complex
03/30/2023
LG Energy Solution Plans Queen Creek, Arizona, EV Battery Manufacturing Plant
03/28/2023
Middle West Spirits Expands Columbus, Ohio, Operations
03/28/2023
Textile Manufacture 23 Farrar Street Relocates-Plans Lynn, Massachusetts, Operations
03/28/2023
Canada-Based Epsilon Industries Plans Tuscaloosa, Alabama, Prefabricated Modular Utility Systems Plant
03/28/2023
Most Read
-
37th Annual Corporate Survey: Economic Pressures Exerting Greatest Effect on Decision-Makers
Q1 2023
-
19th Annual Consultants Survey: Clients Challenged by Tight Labor Market, Energy Availability
Q1 2023
-
The Top Investment Location Prospects for Aerospace Manufacturing
Q1 2023
-
2022 Top States for Doing Business Provide an Environment for Business Growth
Q3 2022
-
Companies Are Recalibrating Their Priorities
Q1 2023
-
How Are Economic Developers Partnering to Solve Workforce Challenges?
Q1 2023
-
Strategies to Overcome Intensifying Industrial Real Estate Challenges
Q1 2023